Scientists have recreated morphine-like pain relief in mice with a targeted therapy that avoids addiction-linked brain circuits.
That separation could open a path to treating chronic pain without the tolerance, overdose risk, and withdrawal that haunt opioids.
Inside pain circuits
In mice with nerve injury, the treatment muted ongoing pain behaviors while leaving basic touch and heat responses unchanged.
By tracing signals, Gregory Corder, PhD, at the University of Pennsylvania’s Perelman School of Medicine (UPENN) tied morphine relief to a small circuit.
Corder then used that map to design a gene therapy that dampened only those opioid-sensitive neurons.
Keeping most brain signaling intact makes room for pain control that does not automatically pull in euphoria or sedation.
Opioids hit many systems
Opioid drugs can blunt pain quickly, but they also tug on brain circuits that regulate reward, breathing, and overdose risk.
After repeated doses, the brain adapts by reducing receptor response, so people need higher amounts for the same effect.
The approach was built to reduce pain while sidestepping the addiction and life-threatening side effects that define opioid treatment, a constraint that shaped the study from the outset.
A brain pain hub
Pain has a sensory side and an emotional side, and opioids often quiet the distress more than the signal.
Near the brain’s midline sits the anterior cingulate cortex, a region that tags pain as unpleasant and urgent.
In the new work, morphine calmed activity in selected neurons there, while reflexive withdrawal from heat stayed normal.
Targeting that emotional layer of pain may reduce suffering without blocking protective warnings that keep people from further injury.
Measuring pain behavior
Standard lab tests often focus on quick reflexes, yet chronic pain changes how an animal moves and rests for long stretches.
To capture that fuller picture, the team built a deep learning system, software that learns patterns from many videos.
Its model watched mice in a dark enclosure and scored behaviors like licking, grooming, and stillness without a person in view.
That automated scoring let the researchers spot pain relief that looked real in daily life, not just in reflex tests.
Morphine in the cortex
Weeks after a nerve injury, mice showed a lasting change in cingulate activity that matched their ongoing discomfort.
Researchers called that state neuropathic pain, pain caused by damaged nerves, and tracked it across repeated sessions.
Morphine pushed those activity patterns back toward baseline, and the animals spent less time in high-pain behavior states.
Linking a drug’s effect to a specific pattern gave the team a target for a more precise treatment.
A genetic control switch
With a cellular target in hand, the team packaged a gene into a virus and delivered it to the same cortex area.
Only the small subset of brain cells normally engaged by opioid painkillers activated the gene, keeping the effect tightly confined to the circuit responsible for pain relief.
Afterward, a separate drug could silence those tagged neurons, creating on-demand relief instead of a constant whole-brain drug effect.
“By targeting the precise brain circuits that morphine acts on, we believe this is a first step in offering new relief for people whose lives are upended by chronic pain,” said Corder.
Relief without tolerance
In mice with chronic nerve pain, a single dose of the activator quickly lowered spontaneous licking and other distress behaviors.
Daily dosing for one week kept that relief steady, suggesting the targeted cells did not build classic opioid tolerance.
Tests of basic sensation stayed largely normal, which matters because numbness can invite new injuries or missed infections.
Longer studies still need to watch for mood changes, since this brain region also helps steer attention and motivation.
Addiction tests in mice
Addiction risk often shows up when animals seek a drug even without pain, so the team looked for that pull.
Uninjured mice did not develop a preference for the chamber linked to brain silencing, a sign of low reinforcement.
Injured mice favored that same chamber, consistent with negative reinforcement where relief becomes rewarding only because pain is present.
That pattern suggests the therapy may calm suffering without creating a new high to chase, at least in mice.
Stakes for pain care
A Centers for Disease Control and Prevention report put the number of adults with chronic pain in 2021 at 52 million.
Beyond medical bills, a National Academies blueprint estimated chronic pain costs the country up to $635 billion each year.
In 2019, drug overdose deaths reached 70,630, and opioids drove 70.6 percent of them in Centers for Disease Control and Prevention numbers.
Across Philadelphia, Pew’s 2025 survey found 44 percent knew someone with opioid use disorder, and one-third knew an overdose victim.
A path beyond opioids
Linking opioid-like relief to a narrow cortex circuit allows the team to design a therapy that can be turned on.
Human trials will require safer delivery and careful monitoring, yet the strategy shows how precision might replace whole-body opioids.
The study is published in Nature.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
—–
